Novel monobactams utilizing a siderophore uptake mechanism for the treatment of gram-negative infections

被引：19

作者：

Mitton-Fry, Mark J. ^{[1
]}

Arcari, Joel T. ^{[1
]}

Brown, Matthew F. ^{[1
]}

Casavant, Jeffrey M. ^{[1
]}

Finegan, Steven M. ^{[3
]}

Flanagan, Mark E. ^{[1
]}

Gao, Hongying ^{[4
]}

George, David M. ^{[3
]}

Gerstenberger, Brian S. ^{[1
]}

Han, Seungil ^{[5
]}

Hardink, Joel R. ^{[4
]}

Harris, Thomas M. ^{[1
]}

Thuy Hoang ^{[1
]}

Huband, Michael D. ^{[3
]}

Irvine, Rebecca ^{[3
]}

Lall, Manjinder S. ^{[1
]}

Lemmon, M. Megan ^{[3
]}

Li, Chao ^{[1
]}

Lin, Jian ^{[4
]}

McCurdy, Sandra P. ^{[3
]}

Mueller, John P. ^{[3
]}

Mullins, Lisa ^{[3
]}

Niosi, Mark ^{[4
]}

Noe, Mark C. ^{[1
]}

Pattavina, David ^{[6
]}

Penzien, Joseph ^{[3
]}

Plummer, Mark S. ^{[1
]}

Risley, Hud ^{[1
]}

Schuff, Brandon P. ^{[1
]}

Shanmugasundaram, Veerabahu ^{[2
]}

Starr, Jeremy T. ^{[1
]}

Sun, Jianmin ^{[1
]}

Winton, Jennifer ^{[4
]}

Young, Jennifer A. ^{[1
]}

机构：

[1] Pfizer Worldwide Res & Dev, Med Chem, Groton, CT 06340 USA

[2] Pfizer Worldwide Res & Dev, Computat Chem, Groton, CT 06340 USA

[3] Pfizer Worldwide Res & Dev, Antibacterials Res Unit, Groton, CT 06340 USA

[4] Pfizer Worldwide Res & Dev, Pharmacokinet Dynam & Metab, Groton, CT 06340 USA

[5] Pfizer Worldwide Res & Dev, Struct Biol, Groton, CT 06340 USA

[6] Pfizer Worldwide Res & Dev, Analyt R&D, Groton, CT 06340 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2012年 / 22卷 / 18期

关键词：

Monobactam; Gram-negative; Pseudomonas aeruginosa; Klebsiella pneumoniae; Escherichia coli; Siderophore; MC-1; BETA-LACTAM ANTIBIOTICS; ANTIBACTERIAL ACTIVITY; CATECHOL MOIETY; CEPHALOSPORINS; MONOCARBAMS; DERIVATIVES; BAL30072;

D O I：

10.1016/j.bmcl.2012.07.005

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

引用

页码：5989 / 5994

页数：6

共 50 条

[31] Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance
Monogue, Marguerite L.
Kuti, Joseph L.
Nicolau, David P.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (03) : 459 - 476
[32] Antibiotics in the Pipeline for Treatment of Infections due to Gram-Negative Organisms
Vissichelli, Nicole C.
Stevens, Michael P.
CURRENT TREATMENT OPTIONS IN INFECTIOUS DISEASES, 2019, 11 (02) : 115 - 144
[33] What's new in the treatment of multidrug-resistant gram-negative infections?
Mo, Yoonsun
Lorenzo, Michael
Farghaly, Sara
Kaur, Kamaljit
Housman, Seth T.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2019, 93 (02) : 171 - 181
[34] Treatment Options for Carbapenem-Resistant Gram-Negative Infections
Fritzenwanker, Moritz
Imirzalioglu, Can
Herold, Susanne
Wagenlehner, Florian M.
Zimmer, Klaus-Peter
Chakraborty, Trinad
DEUTSCHES ARZTEBLATT INTERNATIONAL, 2018, 115 (20-21): : 345 - +
[35] Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections
Falcone, Marco
Paterson, David
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (10) : 2713 - 2722
[36] Treatment of multidrug-resistant Gram-negative skin and soft tissue infections
Jabbour, Jean-Francois
Sharara, Sima L.
Kanj, Souha S.
CURRENT OPINION IN INFECTIOUS DISEASES, 2020, 33 (02) : 146 - 154
[37] Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens
Jorda, Anselm
Zeitlinger, Markus
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (07) : 777 - 791
[38] Antibiotic-Resistant Gram-Negative Bacterial Infections in Patients With Cancer
Perez, Federico
Adachi, Javier
Bonomo, Robert A.
CLINICAL INFECTIOUS DISEASES, 2014, 59 : S335 - S339
[39] Novel Beta Lactam Antibiotics for the Treatment of Multidrug-Resistant Gram-Negative Infections in Children: A Narrative Review
Venuti, Francesco
Romani, Lorenza
De Luca, Maia
Tripiciano, Costanza
Palma, Paolo
Chiriaco, Maria
Finocchi, Andrea
Lancella, Laura
MICROORGANISMS, 2023, 11 (07)
[40] Multidrug-resistant Gram-negative bacterial infections
Macesic, Nenad
Uhlemann, Anne-Catrin
Peleg, Anton Y.
LANCET, 2025, 405 (10474) : 257 - 272

← 1 2 3 4 5 →